CardioExchange Archive

November 18th, 2011

AHA.11 Concludes and Our Fellows Reflect

CardioExchange Editors, Staff, Eiman Jahangir, MD, John Ryan, MD, Amit Shah, MD, MSCR and Reva Balakrishnan, MD, MPH

Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange.  The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. This is their final post. See their complete coverage at the bottom of this post and in this review of our AHA coverage. Readers, […]

---

November 16th, 2011

Evacetrapib – The New Wonder Drug?

Amit Shah, MD, MSCR

Impressive safety and efficacy data on evacetrapib—but it’s too early give odds on whether it’s a true wonder drug or a nightmare like its fellow CETP inhibitor, torceptrapib

---

November 16th, 2011

Was AIM HIGH a Hit or a Miss?

Reva Balakrishnan, MD, MPH

One of the best parts of this conference has been the opportunity to hear experts on the panels dissect and interpret the data following the presentations.

---

November 16th, 2011

ELEVATE-TIMI 56: One New Piece of the Clopidogrel Puzzle

Larry Husten, PHD

Tripling the maintenance dose of clopidogrel in most but not all patients with a common genetic variation will lower platelet reactivity to levels achieved in patients without the variation.

---

November 15th, 2011

An Event, Not a Conference

Eiman Jahangir, MD

Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange.  The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. This is the last day of the conference for me. While I am […]

---

November 15th, 2011

After AIM HIGH, What Future for Niacin? A CardioExchange Panel

CardioExchange Editors, Staff

Steve Nissen, JoAnne Foody, Roger Blumenthal, and AIM HIGH author William Boden weigh in on what patients do and don’t remain good candidates for niacin therapy.

---

November 15th, 2011

MI FREE: A Free Lunch for Patients and Insurers Alike?

John Ryan, MD

Removing copays increased adherence, decreased events, and saved the sponsoring insurance company a tidy sum. So are the issues with insurance-sponsored studies different from those with pharmaceutical-sponsored ones?

---

November 15th, 2011

My First Oral Presentation: Life on the Other Side of the Podium

Amit Shah, MD, MSCR

Not having to drag around a poster container was refreshing, but instead I found myself dragging around my dread about my oral presentation.

---

November 15th, 2011

Finding Wisdom in Unfamiliar Ways in a Familiar Place

Amit Shah, MD, MSCR

The Scientific Sessions are not the only way to learn at AHA.

---

November 14th, 2011

At AHA, the Title Says It All

David Martin, M.D.

. . . or almost. Here are some abstract and session titles that have caught my eye so far: Nightmares in the Cath Lab. A session where fellows presented cases gone wrong. I missed this one and sorry I did. Wonder if TCT had anything similar. My Most Challenging Cases: Shock and Awe in the […]

---